Unnecessary surgeries for suspected, but ultimately benign, ovarian tumors could be reduced if ultrasonography is improved, according to a recent report in The Lancet Oncology. The study showed that the number of surgeries for suspected cancers was significantly higher after routine ultrasounds compared with ultrasounds performed by sonographers who have more than 10 years of experience.
Unnecessary surgeries for suspected, but ultimately benign, ovarian tumors could be reduced if ultrasonography is improved, according to a recent report in The Lancet Oncology. The study showed that the number of surgeries for suspected cancers was significantly higher after routine ultrasounds compared with ultrasounds performed by sonographers who have more than 10 years of experience.
Ultrasound is commonly used for preoperative assessment, but diagnostic accuracy varies with operator experience and skill. Dr. Joseph Yazbek and colleagues at Guy's and St Thomas' Hospital NHS Foundation Trust in London conducted a randomized study to determine whether this operator variation led to differences in management of 165 patients with ovarian abnormalities.
Seventy-seven women at London's regional South-East Gynaecological Cancer Centre received ultrasounds performed by examiners who had more than 10 years of experience in gynecological ultrasonography and were certified teachers of the technique (level III). The remaining 73 patients received ultrasounds performed by technologists trained in gynecological ultrasonography who were certified at level II.
Of the women who received scans by the level II technologists, 37% underwent major surgical staging procedures, compared with 22% of those who received ultrasounds by level III examiners.
The results surprised Yazbek.
"We expected a greater reduction in the number of major operative procedures and more minimally invasive procedures in the level III arm of the study," he said. Other studies have shown that level III ultrasonographers can identify cancerous tumors with 95% accuracy."
In this trial, all cancerous tumors among the women were identified, and level III examiners correctly diagnosed the nature of the abnormalities in all but one of the patients. Level II examiners did so in only 52% of the cases.
"Clinicians still do not have a great belief in the ability of ultrasound to accurately predict the nature of ovarian tumors," Yazbek said. "This will happen with time, by training more specialists in gynecological ultrasound and further improving the diagnostic ability of ultrasound scanning to differentiate benign from malignant ovarian tumors."
Few ultrasonographers specialize in gynecology in the U.K. Training more specialists would help improve the accuracy of diagnoses for patients, according to Dr. Yazbek.
The problem is likely not confined to the U.K.
"In general, ultrasound operator-dependence is well known," said Dr. Leslie Scoutt, chief of the radiology department's ultrasound section at Yale University. Scoutt was not associated with the study.
experience with gynecological ultrasound were more accurate when
characterizing ovarian masses than less experienced technologists.
(Provided by J. Yazbek)
For more information from the Diagnostic Imaging archives:
High-quality ultrasound demonstrates measurable effect in ovarian cancer management
Report from SNM: PET/CT excels in management of recurring ovarian cancer
MSCT assists ovarian mass identification
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Predicting DCIS Upgrade to Invasive Breast Cancer: Can Contrast-Enhanced Ultrasound Have an Impact?
August 21st 2024Adding two key findings from contrast-enhanced ultrasound to a predictive model of mammography, conventional ultrasound and clinicopathological findings led to a 86.1 percent AUROC for predicting the upgrading of ductal carcinoma in situ to invasive breast cancer, according to new research.
Techsomed Launches Ultrasound-Based Software Suite for Liver Tumor Ablation Therapy
July 29th 2024Featuring the previously FDA-cleared BioTraceIO Vision and BioTraceIO Precision modalities, the BioTrace software suite combines real-time ultrasound guidance and advanced AI technology to help bolster outcomes with liver tumor ablation therapy.